Lupitros-Z Eye Drop contains Travoprost 0.004% w/v, a prostaglandin analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Travoprost acts by increasing the outflow of aqueous humor through the uveoscleral pathway, thereby effectively lowering IOP. This medication is typically administered once daily in the affected eye(s), preferably in the evening, to maximize therapeutic efficacy. Clinical studies have demonstrated that Travoprost provides significant and sustained IOP reduction, which is critical in preventing optic nerve damage and preserving visual function. Lupitros-Z Eye Drop is generally well tolerated; however, patients may experience mild ocular side effects such as hyperemia, eyelash growth, or changes in iris pigmentation. It is contraindicated in patients with hypersensitivity to Travoprost or any component of the formulation. Caution is advised in patients with active intraocular inflammation or a history of herpetic keratitis. Proper administration technique is essential to avoid contamination and ensure optimal dosing. Patients should be monitored regularly for IOP response and ocular health during treatment. Lupitros-Z Eye Drop offers a reliable therapeutic option for managing elevated IOP and reducing the risk of glaucoma progression.